Pursuing tumor-infiltrating lymphocytes (TILs), Turnstone Biologics Inc. raised about $80 million in an IPO, offering 6.7 million shares at $12 each. The firm is “pioneering a differentiated approach to TILs,” with next-generation products designed by choosing the most potent and tumor-reactive T cells, dubbed Selected TILs, according to SEC paperwork.